Javier Munoz, MD, MBA

Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.

Moving beyond BTK inhibition in marginal zone lymphoma, expert panelists review other therapies and drug classes with indications in this setting.

Panelists look at the class effects of BTK inhibitors and share optimal strategies to select therapy and manage toxicities.

Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.

A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.

Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.

Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.

Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.